Trial Profile
A study to evaluate the telaprevir, pegylated-interferon-alpha 2b and ribavirin and mutational diversity of NS5A and NS in patients with genotype 1b chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Biomarker; Pharmacodynamics
- 15 Dec 2015 New trial record